Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Teresa Olave"'
Autor:
José Ramón Azanza, José Mensa, José Barberán, Lourdes Vázquez, Jaime Pérez de Oteyza, Mi Kwon, Lucrecia Yáñez, José María Aguado, Antonio Cubillo Gracian, Carlos Solano, Isabel Ruiz Camps, Jesús Fortún, Miguel Salavert Lletí, Carlota Gudiol, Teresa Olave Rubio, Carolina García-Vidal, Montserrat Rovira Tarrats, María Suárez-Lledó Grande, Pedro González-Sierra, Carlos Dueñas Gutiérrez
Publikováno v:
Revista Española de Quimioterapia. 36:236-258
The administration of antifungals for therapeutic and, especially, prophylactic purposes is virtually a constant in patients requiring hematology-oncology treatment. Any attempt to prevent or treat Aspergillus or Mucor infections requires the adminis
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alejandro Lapeña Casado, Carlos Santonja, Mar García‐García, Maria Teresa Olave‐Rubio, Marta Lorda‐Espés, Regina Fink‐Puches, Lorenzo Cerroni, Lucía Prieto‐Torres
Publikováno v:
Journal of Cutaneous Pathology.
Autor:
Montserrat Arnán Sangerman, Ainhoa Fernández Moreno, Antonio García Quintana, Carolina García-Vidal, María Teresa Olave Rubio, María Del Mar Tormo Díaz, Meritxell Vendranas, Gabriela Rodriguez Macias
Publikováno v:
Expert Review of Hematology. 15:203-214
FLT3 inhibitors have been recently introduced as novel treatment targets in patients with FLT3-mutated acute myeloid leukemia (AML). Midostaurin is an oral multikinase inhibitor that targets multiple receptor tyrosine kinases including FLT3 and has b
Autor:
Tamara Castaño-Bonilla, Eva Barragán, Claudia Sargas, Alejandro Sanz, Lorenzo Algarra, Pilar Herrera-Puente, Raimundo García-Boyero, Manuel Barrios, David Martinez-Cuadron, Rebeca Rodriguez-Veiga, Blanca Boluda, Cristina Gil, Josefina Serrano-López, Joaquín Martínez-López, María José Sayas-Lloris, María Teresa Olave, Rosalía Riaza-Grau, Teresa Bernal-Del Castillo, María José Larrayoz, Raquel Amigo, Antonio Jiménez-Velasco, Joaquín Sánchez, Rosa Ayala, Carlos Blas, Daniel Lainez, Juana Serrano-López, Miguel A. Sanz, Juan M. Alonso-Domínguez, Pau Montesinos
Publikováno v:
DIS MARKERS
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Gemtuzumab ozogamicin (GO) is a conjugate of a monoclonal antibody and calicheamicin, which has been reapproved for the treatment of acute myeloid leukemia (AML). AML patients with the CD33 rs12459419 CC genotype might benefit from the addition of GO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534f113f6c405fdb031c82dd64c37cb5
https://downloads.hindawi.com/journals/dm/2022/3132941.pdf
https://downloads.hindawi.com/journals/dm/2022/3132941.pdf
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Bobes, Alejandro, Tormo, Mar, Diaz-Beya, Marina, Beneit, Paola, Botella, Carmen, Fernández Moreno, Ainhoa, Sampol Mayol, Antonia, Arnan Sangerman, Montserrat, Yeguas Bermejo, Ana, de la Luz Amigo, Maria, Labrador, Jorge, García Guinon, Antoni, Garrido, Ana, Serrano, Josefina, Vives Polo, Susana, García Fortes, Maria, José Sayas, Maria, Miguel Bergua, Juan, Teresa Olave, María, Vall-Llovera, Ferran, Bargay, Juan, Pereiro Sanchez, María, García Boyero, Raimundo, Diaz-Lopez, Antonio, de la Fuente, Adolfo
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S172-S172
Autor:
Francisco-Javier Peñalver, Juan-Manuel Sancho, Adolfo de la Fuente, María-Teresa Olave, Alejandro Martín, Carlos Panizo, Elena Pérez, Antonio Salar, Alberto Orfao
Publikováno v:
Haematologica, Vol 102, Iss 2 (2017)
Diffuse large B-cell lymphoma patients have a 5% overall risk of central nervous system events (relapse or progression), which account for high morbidity and frequently fatal outcomes,1 and shortened overall survival of
Externí odkaz:
https://doaj.org/article/c70390b0a7414dde8c7290bf4020d98c
Autor:
Tamara, Castaño-Bonilla, Eva, Barragán, Claudia, Sargas, Alejandro, Sanz, Lorenzo, Algarra, Pilar, Herrera-Puente, Raimundo, García-Boyero, Manuel, Barrios, David, Martinez-Cuadron, Rebeca, Rodriguez-Veiga, Blanca, Boluda, Cristina, Gil, Josefina, Serrano-López, Joaquín, Martínez-López, María José, Sayas-Lloris, María Teresa, Olave, Rosalía, Riaza-Grau, Teresa Bernal-Del, Castillo, María José, Larrayoz, Raquel, Amigo, Antonio, Jiménez-Velasco, Joaquín, Sánchez, Rosa, Ayala, Carlos, Blas, Daniel, Lainez, Juana, Serrano-López, Miguel A, Sanz, Juan M, Alonso-Domínguez, Pau, Montesinos
Publikováno v:
Disease markers. 2022
Gemtuzumab ozogamicin (GO) is a conjugate of a monoclonal antibody and calicheamicin, which has been reapproved for the treatment of acute myeloid leukemia (AML). AML patients with the
Autor:
Jesus Feliu, Mercedes Rodríguez-Calvillo, Ricardo García-Muñoz, Pilar Giraldo, Ángel Panizo, Susana Inogés, Jorge M. Núñez-Córdoba, Eva Bandrés, Ascensión López-Díaz de Cerio, Nicolas Martinez-Calle, Marcio Andrade-Campos, Esther Pena, Carlos Panizo, Carlos Grande, María Teresa Olave
Publikováno v:
British Journal of Haematology. 189:1064-1073
Anti-cluster of differentiation 20 (CD20) monoclonal antibodies (mAbs) have shown promise in follicular lymphoma (FL) as post-induction therapy, by enhancing antibody-dependent cellular cytotoxicity (ADCC). However, cytotoxic cells are reduced after